Resolution R5-2021-e

Investments within the ACT-A Oxygen Emergency Response

Reiterating the Executive Board’s full support for Unitaid’s engagement in the global response to COVID-19, including Unitaid’s leadership role as the co-convenor of the Access to COVID-19 Technologies Accelerator (ACT-A) Therapeutics Partnership; and acknowledging the importance of the ACT-A Oxygen Emergency Response as an integral part of the work of this Partnership; and

Recalling the Executive Board Information Session of 3 March 2021, during which the Secretariat highlighted the potential for Unitaid to play a key role in accelerating and catalyzing access to medical oxygen in low and middle-income countries, working with an emergency task force composed of other global health partners to deliver a coordinated ACT-A Oxygen Emergency Response;

The Board confirms its support for Unitaid’s engagement in this area and authorises the Secretariat to initially commit up to USD $10 million for interventions in line with ACT-A’s priorities, in response to the medical oxygen emergency. These investments shall be funded through additional contributions received for the COVID-19 response. Investments shall be selected and funds committed in accordance with Unitaid’s Board-approved processes for the management of new investments funded through additional contributions received for COVID-19, as set out in document UNITAID/EB35/2020/6 and adopted by the Board in Resolution EB35/2020/R4.

The Board will keep the funding requirements for this area under review and the Secretariat is requested to mobilise further additional contributions to fund this area of work, with a view to increasing the initial USD $10 million funding ceiling established under this Resolution.

Marisol Touraine
Chair of the Unitaid Executive Board

Date: 5 March 2021